Complement Levels and Risk of Organ Involvement in Patients with Systemic Lupus Erythematosus

Al-Fadl, Esam M. Abu; Radwan, Ahmed; Ali, Ahmed M.; Masoud, Abeer H.

doi:10.21608/svuijm.2019.122274

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study included 90 participants: 30 healthy controls (HCs) and 60 patients with SLE; most of them were females (80%) and with a mean age of 27.79±9.16 years. This agrees with the findings of Abu Al-Fadl et al 16 , who found that 92% of the cases were females and only 8% were males.…”

Section: Discussionsupporting

confidence: 93%

Anti-C1q antibodies as a specific serological marker In patients with active lupus nephritis

Sayed,

Hassan,

Mohamed

et al. 2023

Aswan University Medical Journal

View full text Add to dashboard Cite

Background: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, lupus nephritis (LN) is a widespread and serious complication and it is responsible for morbidity and mortality. This study aimed to detect the correlation between anti-C1q antibodies and LN activity. Patients and Methods: A casecontrol study was conducted from September 2021 to September 2022, consisted of 30 healthy controls and 60 patients with SLE. The patients were divided into two groups: group 1 with active LN and group 2 with absent LN. Results: The current study consisted of 72 females and 18 males. Regarding the renal biopsy, there were 8 (26.7%) patients in class I, 3 (10.0%) patients in class II, 11 (36.7%) patients in class III and 8 (26.7%) patients in class IV. Our study found a significant difference between groups 1, 2 and the control group regarding Albumin/creatinine ratio, e GFR, SLEDAI score, and anti-C1q. We also revealed a significant positive correlation between anti-C1q and SLEDAI score, Urea, Creat, and Albumin/creatinine ratio in all studied groups. Conclusion: Anti-C1q antibodies may serve as a reliable serological indicator for identifying SLE individuals with active LN and active SLE disease.

show abstract

Section: Discussionsupporting

confidence: 93%